Figure 4.

Effects of CYB5A in vivo. A) Five days after injection, primary tumors were detectable in all mice (ie, 100% take rate, without surgery-related mortality), and Fluc activity (proportional to the number of cancer cells, carrying Fluc/mCherry) increased over time. B) BLI signal of the pancreatic ductal adenocarcinoma patients (PDAC) tumors as detected in the blood samples with the Gluc (proportional to the number of cancer cells, carrying Gluc/CFP). P values were calculated with two-sided Student t test. C) Survival curves in the two groups of mice. Statistically significant differences were determined by two-sided log-rank test. The number of mice at risk in each group is given below the graph. D) Number of liver metastases in the two groups of mice. All mice were also evaluated for the presence of metastatic localization in other organs, and lung metastases were identified in two of six animals of the control (CTR) group. P values were calculated with two-sided Student t test. E) Immunofluorescence image of a representative section showing a liver metastasis in a mouse from the CYB5A+ group (YFP-positive cells). Points or columns indicate mean values obtained from the analysis of the six mice in each group. Bars indicate standard deviation. *P < .05.